Research programme: Alzheimer's disease therapeutic - Institute of Medicinal Molecular DesignAlternative Names: IMD-4690
Latest Information Update: 16 Jul 2016
At a glance
- Originator Institute of Medicinal Molecular Design
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Japan (PO)